It is a common sense that the current SAP is the first.
If a trial is to test human strength in running, the initial test design of DCVax-L is to test 400m or 800m as it had been usually done with chemo drugs, an old fashion way, and an obsolete test matrix for immuno drugs/agents/vaccines that we have all well understood today. Now it's all known the best way to test/measure is to run a marathon instead -- a 42.2 km long running.
Today nobody thinks a good result of 400m or 800m run (test) would indicate/correlate a good result of a marathon run. So mOS in cancer vaccine test is obsolete and useless in measuring OS for cancer patients.
Nobody would think the measurement matrix (SAP in our case) for 400m and 800m running (tests) would be the same SAP (test measurements) for a 42.2 km long marathon run.
Therefore, there are no tweaks or tricks naturally in changing a matrix (SAP) initially designed for a short distance run (immuno test with chemo test measurement matrix) to a matrix (SAP) of a marathon run (immuno test).
So in my book, the current SAP is the first of its kind. I would not even call it revised, because nothing there need to be revised, and it's all pioneering, genuine and original.
And the wolfpack don't think that way, I believe FDA would think the same as I stated above.
BTW, today nwbo's market cap at the present is still below $250 million, and a share price per share of about $0.36.
Does it reflect its potential which will be known within a month?
Market Data 
Markets 
AI
